Adverse reactions associated with henna-based cosmetic products: a twenty-two-year pharmacovigilance analysis of the FDA adverse event reporting system

Henna-based cosmetic products, particularly those adulterated with para-phenylenediamine (PPD), are an increasingly recognized cause of adverse skin reactions. Despite widespread consumer use, population-level pharmacovigilance data from US regulatory sources remain limited. To characterize the clinical, demographic, and temporal patterns of henna-associated adverse events reported to the US Food and Drug Administration (FDA), and to identify factors associated with case seriousness. Retrospective cross-sectional analysis of henna-related adverse event reports extracted from the FDA Adverse Event Reporting System Cosmetic Public Dashboard, excluding products unrelated to henna (Lawsonia inermis) such as Jagua-based formulations. Statistical analyses included chi-square, Spearman’s rank correlation, and Proportional Reporting Ratio disproportionality analysis. A total of 110 cases were identified (female: 65.5%; pediatric cases <18 years). Black Henna products (classified by product name) represented the largest product category (n = 47, 42.7%). The most frequently reported reactions were pruritus (39.3%), hypersensitivity (32.1%). Serious cases 50.0% of the dataset. No statistically significant association was found between gender and seriousness (χ2=0.133, p = 0.715). hypersensitivity (PRR = 1.54, 95% CI: 0.81–2.92, χ2=1.74, p = 0.187) and urticaria (PRR = 2.26, 95% CI: 0.82–6.18, χ2=2.51, p = 0.113) showed elevated PRR values; however, neither met the predefined signal threshold (PRR ≥ 2.0, χ2≥4.0, n ≥ 3), and no formal disproportionality signal was identified. Henna-associated adverse events affect predominantly young females and pediatric patients. These findings support enhanced regulatory scrutiny under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), mandatory product labeling, and targeted consumer safety communication. What this study addsA comprehensive pharmacovigilance analysis of henna-related ADRs.Black henna (PPD-containing) products account for 42% of all cases; 49.1% of all reports are classified as serious events.Clinician should enquire about temporary tattoo exposure in patients with unexplained ACD; PPD patch testing is indicated; consumer safety labeling at body art venues requires regulatory reinforcement. A comprehensive pharmacovigilance analysis of henna-related ADRs. Black henna (PPD-containing) products account for 42% of all cases; 49.1% of all reports are classified as serious events. Clinician should enquire about temporary tattoo exposure in patients with unexplained ACD; PPD patch testing is indicated; consumer safety labeling at body art venues requires regulatory reinforcement.

Authors

Publication Details

Journal
Figshare
Published
2026-11-14
DOI
https://doi.org/10.6084/m9.figshare.35011472
Primary Topic
Contact Dermatitis and Allergies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Adverse reactions associated with henna-based cosmetic products: a twenty-two-year pharmacovigilance analysis of the FDA adverse event reporting system

Nagalakshmi Narasimhaswamy, Shyamala Ganesan, Basavaraj Poojar
Figshare
Contact Dermatitis and Allergies
article

Adverse reactions associated with henna-based cosmetic products: a twenty-two-year pharmacovigilance analysis of the FDA adverse event reporting system

Nagalakshmi Narasimhaswamy, Shyamala Ganesan, Basavaraj Poojar
article en

Abstract

Henna-based cosmetic products, particularly those adulterated with para-phenylenediamine (PPD), are an increasingly recognized cause of adverse skin reactions. Despite widespread consumer use, population-level pharmacovigilance data from US regulatory sources remain limited. To characterize the clinical, demographic, and temporal patterns of henna-associated adverse events reported to the US Food and Drug Administration (FDA), and to identify factors associated with case seriousness. Retrospective cross-sectional analysis of henna-related adverse event reports extracted from the FDA Adverse Event Reporting System Cosmetic Public Dashboard, excluding products unrelated to henna (Lawsonia inermis) such as Jagua-based formulations. Statistical analyses included chi-square, Spearman’s rank correlation, and Proportional Reporting Ratio disproportionality analysis. A total of 110 cases were identified (female: 65.5%; pediatric cases <18 years). Black Henna products (classified by product name) represented the largest product category (n = 47, 42.7%). The most frequently reported reactions were pruritus (39.3%), hypersensitivity (32.1%). Serious cases 50.0% of the dataset. No statistically significant association was found between gender and seriousness (χ2=0.133, p = 0.715). hypersensitivity (PRR = 1.54, 95% CI: 0.81–2.92, χ2=1.74, p = 0.187) and urticaria (PRR = 2.26, 95% CI: 0.82–6.18, χ2=2.51, p = 0.113) showed elevated PRR values; however, neither met the predefined signal threshold (PRR ≥ 2.0, χ2≥4.0, n ≥ 3), and no formal disproportionality signal was identified. Henna-associated adverse events affect predominantly young females and pediatric patients. These findings support enhanced regulatory scrutiny under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), mandatory product labeling, and targeted consumer safety communication. What this study addsA comprehensive pharmacovigilance analysis of henna-related ADRs.Black henna (PPD-containing) products account for 42% of all cases; 49.1% of all reports are classified as serious events.Clinician should enquire about temporary tattoo exposure in patients with unexplained ACD; PPD patch testing is indicated; consumer safety labeling at body art venues requires regulatory reinforcement. A comprehensive pharmacovigilance analysis of henna-related ADRs. Black henna (PPD-containing) products account for 42% of all cases; 49.1% of all reports are classified as serious events. Clinician should enquire about temporary tattoo exposure in patients with unexplained ACD; PPD patch testing is indicated; consumer safety labeling at body art venues requires regulatory reinforcement.

Figshare
Contact Dermatitis and Allergies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon